Recommendations on universal health care coverage in India

10 April 2012

India Health Progress has released the analysis presented by Dileep Malvankar, Dean of Public Health, Gandhinagar, on the recommendations made by the High Level Expert Group for the implementation of universal health care coverage in India by 2022.

The activity is part of the nationwide campaign “Health Access Week” organized by India Health Progress. Health Access Week is a unique flagship event started in 2011 with the intent to sensitize stakeholder groups on the lack of access to healthcare in the country and amplify voices on this critical issue.

Aman Gupta, principal advisor at India Health Progress, said: “Universal health care access cannot be achieved in isolation. Given the complex interplay of obstacles that encapsulate healthcare access, a holistic approach needs to be taken to address the entire gamut of core healthcare issues.”

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight





More Features in Generics